Mercer Global Advisors
BEAM icon

Mercer Global Advisors’s Beam Therapeutics BEAM Stock Holding History

Mercer Global Advisors’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,821
Closed -$268K – 2158
2024
Q4 		$268K Sell
10,821
-4,568
-30% -$117K ﹤0.01% 1813
2024
Q3 		$360K Sell
15,389
-622
-4% -$16.1K ﹤0.01% 1528
2024
Q2 		$375K Sell
16,011
-1,264
-7% -$31K ﹤0.01% 1465
2024
Q1 		$571K Buy
17,275
+5,036
+41% +$157K ﹤0.01% 1206
2023
Q4 		$333K Buy
12,239
+779
+7% +$19.4K ﹤0.01% 1539
2023
Q3 		$276K Buy
11,460
+1,866
+19% +$50K ﹤0.01% 1580
2023
Q2 		$306K Buy
9,594
+1,764
+23% +$57.2K ﹤0.01% 1502
2023
Q1 		$240K Buy
+7,830
New +$309K ﹤0.01% 1632
2022
Q4 		– Sell
-4,683
Closed -$223K – 1932
2022
Q3 		$223K Buy
+4,683
New +$267K ﹤0.01% 1574

Other funds holding BEAM

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Mercer Global Advisors's BEAM Position: Q1 2025 in Review

Mercer Global Advisors sold out of Beam Therapeutics (BEAM) in Q1 2025, closing a stake of 10,821 shares — an estimated $268K sold.

Mercer Global Advisors first reported a position in BEAM in Q3 2022 and held it in 9 quarters. The position peaked at $571K in Q1 2024. 238 funds tracked by Wall St. Rank hold BEAM as of Q1 2025.

  • Mercer Global Advisors reported no remaining Beam Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Mercer Global Advisors sold 10,821 Beam Therapeutics shares in Q1 2025, an estimated $268K.
  • Mercer Global Advisors first reported a position in Beam Therapeutics in Q3 2022 and held it in 9 quarters.
  • Mercer Global Advisors's Beam Therapeutics position peaked at $571K in Q1 2024.
  • 238 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2025.

Based on Mercer Global Advisors's 13F filing for Q1 2025, filed 15 May 2025.